Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Troplasminogen alfa

Drug Profile

Troplasminogen alfa

Alternative Names: BB-10153; Tapgen; V-10153

Latest Information Update: 17 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Class Anti-ischaemics; Antiarrhythmics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 25 Aug 2015 Discontinued - Phase-II for Stroke in USA, Canada, Czech Republic, Denmark and Hungary (IV)
  • 12 Nov 2010 V 10153 is available for licensing in World as of 28 Feb 2000. http://www.vernalis.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top